Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus CHLOR TRIMETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus CHLOR TRIMETON.
BENADRYL vs CHLOR-TRIMETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Chlorpheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, thereby preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, bronchoconstriction, and sensory nerve stimulation.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
4 mg orally every 4-6 hours, not exceeding 24 mg/day. Also available as 8 mg or 12 mg extended-release tablets once daily at bedtime.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life is 12-15 hours in adults, with clinical context: the antihistamine effect persists longer than plasma levels due to active metabolite production and tissue binding.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Primarily hepatic metabolism (N-dealkylation and oxidative pathways); renal excretion of metabolites accounts for ~70% of elimination, with <1% excreted unchanged in urine. Fecal elimination is negligible (<5%).
Category C
Category C
Antihistamine
Antihistamine